skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.02d (Release date: 2016-02-27)
SearchBox Top
SearchBox Bottom
JAK2 Inhibitor TG101348 (Code C88293)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: JAK2 Inhibitor TG101348

Definition: An orally bioavailable, small-molecule, ATP-competitive inhibitor of Janus-associated kinase 2 (JAK2) with potential antineoplastic activity. JAK2 inhibitor TG101348 competes with JAK2 as well as the mutated form AK2V617F for ATP binding, which may result in inhibition of JAK2 activation, inhibition of the JAK-STAT signaling pathway, and the induction of tumor cell apoptosis. JAK2 is the most common mutated gene in bcr-abl-negative myeloproliferative disorders (MPDs); the mutated form JAK2V617F has a valine-to-phenylalanine modification at position 617 and plays a key role in tumor cell proliferation and survival.

Display Name: JAK2 Inhibitor TG101348

Label: JAK2 Inhibitor TG101348

NCI Thesaurus Code: C88293 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C2353170  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
JAK2 Inhibitor TG101348
SAR302503
TG101348

External Source Codes: 
PDQ Closed Trial Search ID 657793
PDQ Open Trial Search ID 657793 (check for NCI PDQ open clinical trial info)
UMLS CUI C2353170

Other Properties:
Name Value (qualifiers indented underneath)
code C88293
Contributing_Source CTRP
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  

URL: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C88293

Mainbox Bottom